Y0001101
Interferon β-1a
European Pharmacopoeia (EP) Reference Standard
Faça loginpara ver os preços organizacionais e de contrato
About This Item
Produtos recomendados
grau
pharmaceutical primary standard
família API
interferon
fabricante/nome comercial
EDQM
aplicação(ões)
pharmaceutical (small molecule)
formato
neat
Condições de expedição
dry ice
temperatura de armazenamento
−70°C
Descrição geral
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Aplicação
Interferon β-1a EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Embalagem
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Outras notas
Sales restrictions may apply.
produto relacionado
Nº do produto
Descrição
Preços
Código de classe de armazenamento
10 - Combustible liquids
Classe de risco de água (WGK)
WGK 3
Ponto de fulgor (°F)
Not applicable
Ponto de fulgor (°C)
Not applicable
Choose from one of the most recent versions:
Certificados de análise (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Atendimento ao cliente
Já possui este produto?
Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.
Normand E Allaire et al.
BMC research notes, 6, 8-8 (2013-01-08)
Clinical trials offer a unique opportunity to study human disease and response to therapy in a highly controlled setting. The application of high-throughput expression profiling to peripheral blood from clinical trial subjects could facilitate the identification of transcripts that function
F Wild
Der Nervenarzt, 84(2), 202-208 (2012-12-18)
For persons covered by statutory health insurance (SHI) an increase in the number of defined daily doses (DDD) for pharmaceuticals to treat multiple sclerosis (MS) is known but so far there has been no comparable survey for private health insurance
Diego Cadavid et al.
PloS one, 8(1), e53297-e53297 (2013-01-12)
There is an unmet need for disease-modifying therapies to improve ambulatory function in disabled subjects with multiple sclerosis. Assess the effects of natalizumab on ambulatory function in disabled subjects with relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS).
Tae Ikeda et al.
No to hattatsu = Brain and development, 45(1), 49-52 (2013-04-19)
We report a case of a 15-year-old girl with relapsing-remitting multiple sclerosis (MS) who received cyclophosphamide pulse therapy. At the age of 5 years, she displayed symptoms such as headache and unconsciousness after varicella infection as the first episode of
Jeffrey A Cohen et al.
Lancet (London, England), 380(9856), 1819-1828 (2012-11-06)
The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a phase 2 trial of previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of first-line alemtuzumab compared with interferon beta 1a in a phase 3
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
Entre em contato com a assistência técnica